Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the ...

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...

Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory ...

Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

4 analysts have expressed a variety of opinions on Becton Dickinson BDX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...